opgen
provides
business
pipeline
update
announces
preliminary
unaudited
revenue
cash
position
third
quarter
opgen
takes
strategic
steps
expand
unyvero
platform
product
pipeline
focus
pending
acuitas
amr
gene
panel
isolates
fda
clearance
expects
invest
significantly
bioinformatics
opgen
subsidiary
ares
genetics
received
notification
exercise
option
negotiate
potential
future
license
ivd
partner
opgen
discontinue
acuitas
amr
gene
panel
urine
clinical
trial
discontinue
fish
product
line
globally
total
revenue
approximately
million
dollars
maintained
strong
balance
sheet
million
cash
september
gaithersburg
globe
newswire
opgen
nasdaq
opgn
opgen
precision
medicine
company
harnessing
power
molecular
diagnostics
bioinformatics
help
combat
infectious
disease
announced
today
total
preliminary
unaudited
revenue
third
quarter
approximately
million
thousand
third
quarter
preliminary
financial
results
three
months
ended
september
reflect
consummation
business
combination
curetis
gmbh
april
results
nine
months
ended
september
included
company
quarterly
report
form
earnings
release
third
quarter
opgen
cash
september
approximately
million
company
also
expanded
capacity
atm
program
additional
million
continues
access
additional
million
tranche
debt
financing
related
r
programs
european
investment
bank
addition
company
announced
details
regarding
strategic
reprioritization
product
portfolio
platform
pipeline
priorities
going
forward
reprioritization
based
feedback
extensive
market
research
customer
survey
stakeholders
decision
making
new
diagnostic
platforms
key
opinion
leader
interviews
conducted
independent
market
research
firm
past
two
quarters
following
review
research
opgen
board
decided
consolidate
company
product
portfolio
proprietary
unyvero
platform
unique
bioinformatics
capabilities
result
change
priority
company
anticipates
following
key
impacts
product
portfolio
going
forward
centered
around
rapid
molecular
diagnostic
platform
offerings
increased
focus
value
added
bioinformatics
solutions
including
ares
genetics
next
generation
artificial
intelligence
powered
amr
ast
prediction
capabilities
following
successful
completion
three
phases
partnered
r
program
announced
earnings
call
ares
genetics
recently
received
formal
notification
undisclosed
global
leading
ivd
corporation
partner
exercised
option
exclusively
negotiate
ares
genetics
scope
terms
potential
exclusive
license
arrangement
ares
ares
genetics
technology
field
human
clinical
diagnostics
coming
months
platform
consolidation
realize
significant
operational
synergies
cost
savings
time
fewer
products
platforms
would
need
maintained
regulatory
quality
management
logistics
service
standpoint
unyvero
platform
product
portfolio
expanded
beyond
lower
respiratory
tract
infections
pneumonia
lrt
lrt
bal
include
complicated
urinary
tract
infections
cuti
invasive
joint
infections
iji
clinical
trials
future
fda
submission
clearance
anticipated
start
products
indications
fully
developed
already
marked
commercially
available
europe
markets
acuitas
amr
gene
panel
isolates
expected
see
near
term
clearance
decision
fda
opgen
october
submission
formal
response
fda
january
request
additional
information
ai
request
cleared
fda
opgen
anticipates
swift
commercial
launch
following
months
legacy
fish
products
business
including
quick
pna
discontinued
europe
rest
world
last
production
lots
manufactured
early
acuitas
amr
gene
panel
urine
clinical
trial
discontinued
focus
shifts
unyvero
platform
complicated
uti
indication
well
additional
future
applications
company
also
announced
accomplishment
following
key
milestones
third
quarter
year
date
opgen
subsidiary
curetis
gmbh
obtained
ce
mark
certification
european
union
kit
pulb
detection
virus
causes
opgen
announced
subsidiary
ares
genetics
gmbh
austrian
national
digitization
award
also
nominated
th
austrian
innovation
award
artificial
intelligence
powered
sequencing
based
molecular
antibiotic
susceptibility
test
marketed
brand
name
aresupa
universal
pathogenome
assay
austrian
innovation
award
artificial
intelligence
powered
sequencing
based
molecular
antibiotic
susceptibility
test
marketed
brand
name
aresupa
universal
pathogenome
assay
opgen
subsidiary
curetis
gmbh
received
eur
thousand
grant
funding
collaboration
project
infectognostics
campus
jena
university
hospital
opgen
subsidiary
ares
genetics
gmbh
collaboration
researchers
johns
hopkins
university
school
medicine
announced
publishing
study
modifiable
risk
factors
emergence
resistance
aeruginosa
journal
clinical
infectious
diseases
opgen
announced
release
new
publication
demonstrates
clinical
utility
unyvero
lrt
panel
potential
impact
antibiotic
use
hospitalized
patients
suspected
pneumonia
compared
treatment
directed
based
microbiological
culture
results
opgen
successfully
completed
study
collaboration
karolinska
institutet
bacterial
pneumonia
patients
data
unyvero
hpn
panel
presented
karolinska
investigators
eccvid
opgen
significantly
improved
working
capital
position
third
quarter
sale
approximately
million
shares
common
stock
company
atm
program
exercise
warrants
october
financing
gross
proceeds
million
third
quarter
nine
months
ended
september
company
sold
approximately
million
shares
common
stock
company
atm
program
upon
exercise
warrants
october
offering
gross
proceeds
million
german
federal
ministry
economic
affairs
energy
bmwi
concluded
investigation
opgen
business
combination
curetis
regards
impact
public
order
security
federal
republic
germany
well
national
healthcare
interests
light
current
pandemic
action
expected
federal
government
matter
oliver
schacht
president
ceo
opgen
commented
opgen
reported
solid
third
quarter
given
persistent
challenging
environment
caused
pandemic
addition
announcing
ce
mark
certification
kit
also
highlighted
publication
several
studies
believe
following
portfolio
consolidation
strategic
product
pipeline
decisions
taken
board
opgen
along
subsidiary
companies
curetis
gmbh
ares
genetics
gmbh
focused
molecular
diagnostics
platform
strategy
growing
emphasis
bioinformatics
offerings
generate
shareholder
value
truly
excited
future
prospect
company
convinced
strategic
initiatives
provide
strong
growth
opportunities
secure
future
global
leader
infectious
diseases
amr
preliminary
financial
results
estimates
prior
completion
opgen
financial
closing
procedures
review
procedures
external
auditors
therefore
may
subject
adjustment
actual
results
available
opgen
opgen
gaithersburg
md
usa
precision
medicine
company
harnessing
power
molecular
diagnostics
bioinformatics
help
combat
infectious
disease
along
subsidiaries
curetis
gmbh
ares
genetics
gmbh
developing
commercializing
molecular
microbiology
solutions
helping
guide
clinicians
rapid
actionable
information
life
threatening
infections
improve
patient
outcomes
decrease
spread
infections
caused
microorganisms
mdros
opgen
product
portfolio
includes
unyvero
acuitas
amr
gene
panel
lighthouse
ares
technology
platform
including
aresdb
using
ngs
technology
bioinformatics
solutions
antibiotic
response
prediction
information
please
visit
statements
press
release
includes
statements
regarding
opgen
third
quarter
results
company
strategic
portfolio
product
pipeline
priorities
ongoing
integration
opgen
acquired
subsidiaries
curetis
gmbh
ares
genetics
gmbh
impact
company
general
market
conditions
statements
statements
regarding
opgen
future
plans
goals
constitute
statements
within
meaning
section
securities
act
section
securities
exchange
act
intended
qualify
safe
harbor
liability
established
private
securities
litigation
reform
act
statements
subject
risks
uncertainties
often
difficult
predict
beyond
control
may
cause
results
differ
materially
expectations
factors
could
cause
results
differ
materially
described
include
limited
ability
successfully
timely
develop
seek
obtain
regulatory
clearance
commercialize
product
services
offerings
rate
adoption
products
services
hospitals
healthcare
providers
realization
expected
benefits
business
combination
transaction
curetis
gmbh
success
commercialization
efforts
impact
company
operations
financial
results
commercialization
efforts
well
capital
markets
general
economic
conditions
effect
business
existing
new
regulatory
requirements
economic
competitive
factors
discussion
significant
risks
uncertainties
associated
opgen
business
please
review
filings
securities
exchange
commission
cautioned
place
undue
reliance
statements
based
expectations
date
press
release
speak
date
press
release
undertake
obligation
publicly
update
revise
statement
whether
result
new
information
future
events
otherwise
opgen
oliver
schacht
president
ceo
investorrelations
opgen
press
contact
matthew
bretzius
fischtank
marketing
pr
matt
opgen
investor
contact
megan
paul
edison
group
mpaul
